58 Charles St
36 articles with GNS Healthcare
GNS Healthcare Presents Novel Use of AI to Identify Drivers of Response to Immune Checkpoint Inhibitor Therapy
AI-driven in silico patients used to accurately identify types of immune responses in head and neck squamous cell carcinoma and non-small cell lung cancer
A transformative innovation Gemini™, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma [25-June-2020] CAMBRIDGE, Mass. , June 25, 2020 /PRNewswire/ -- GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM , the in silico multiple myelom
GNS Healthcare and Multiple Myeloma Research Foundation (MMRF) Announce a Five-Year Collaboration to Advance Precision Medicine
Partnership Aims to Answer Key Questions in Multiple Myeloma Patient Care and Accelerate Discovery and Development of New Treatments
GNS Healthcare, a leading AI-driven precision medicine, announced results of a recently published collaboration that uncovered transcription factor PHF19 as a novel marker of aggressive multiple myeloma progression in newly diagnosed patients.
GNS Healthcare is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company's leadership team as a consultant to advance the company's health plan offerings and drive clinical analytics efforts across GNS, particularly within biopharma market-access and value-based drug collaborations between biopharma and payers..
Cigna Ventures taps GNS' technology and solutions to further advance whole person health for Cigna's customers and clients
GNS Healthcare (GNS), a leading precision medicine company, announced today that former FDA Commissioner Scott Gottlieb, M.D. will be keynoting its 2nd annual Precision Medicine and AI Forum on June 14th in Cambridge
10/8/2018Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
GNS Healthcare a leading precision medicine company, has tapped data analytics veteran David Gascoigne as its Chief Operating Officer.
Clinical and Machine Learning Expert, Dr. Ziad Obermeyer Joins GNS Healthcare's Strategic Advisory Board
GNS Healthcare today announced the appointment of Ziad Obermeyer, MD, Associate Professor of Health Policy and Management at the UC Berkeley School of Public Health, to its strategic advisory board.
Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in Metastatic Colorectal Cancer
Collaboration to apply causal artificial intelligence and clinical trial data to identify factors that drive treatment response in patients with metastatic colorectal cancer
GNS Healthcare to combine its powerful, causal machine learning technology with the comprehensive Answer ALS patient datasets
SomaLogic Licenses GNS Healthcare's REFS™ technology for analysis of its SOMAscan®-derived proteomic data
Combining the world-leading proteomic and artificial intelligence/machine learning technologies to produce novel, actionable health insights across many diseases, conditions and markets
GNS Healthcare and Alliance for Clinical Trials in Oncology Present Results of Causal Modeling that Identifies Clinical and Molecular Drivers of Survival in Colorectal Cancer Patients
Results presented at ASCO 2018 Annual Meeting in Chicago show drivers at baseline allow better risk stratification at initiation of treatment
GNS Healthcare Names Ted Goldstein, Silicon Valley Tech Innovator and Scientific Program Director of Computational Health at UCSF to its Strategic Advisory Board
GNS Healthcare announced the appointment of Dr. Ted Goldstein, Scientific Program Director of Computational Health of University of California, San Francisco, to its Strategic Advisory Board (SAB).
"David's expertise in artificial intelligence and machine learning will be an invaluable asset to GNS' Strategic Advisory Board," said Colin Hill, Chairman, CEO and co-founder of GNS Healthcare.
AI-Driven Discovery Of Novel Predictors Of Parkinson's Disease Progression By GNS Healthcare Appears In The Lancet Neurology
GNS Healthcare Announces Collaboration To Power Cancer Drug Development With REFS Causal Machine Learning And Simulation AI Platform
GNS Healthcare Uncovers Novel Targets For Triple-Negative Breast Cancer Using Causal Machine Learning And Simulation Platform REFS